Dive Brief: Intellia Therapeutics, a leading developer of CRISPR-based medicines, on Thursday said it will buy privately held Rewrite Therapeutics for $45 million, as it …
Gene editing’s promise is clearest, and perhaps closest, in sickle cell disease, a hereditary condition characterized by deformed, or “sickled,” red blood cells that cause …
Before it rose to prominence as a vaccine maker, Moderna’s original ambitions were to use its messenger RNA technology — a way to prompt the …
Mammoth’s evolution into a drugmaker appears to be paying off. Three years ago, the company formed with a plan to use CRISPR gene editing to …
Vertex is best known for its work in cystic fibrosis, having developed four approved medicines that, by the company’s estimates, can treat about 90% of …
Oxford Genetics, a leading innovator of biopharmaceutical technologies, has signed a licensing agreement with world-class service organization, Aldevron to bring to market a standardized range …
U.S. regulators have placed a clinical hold on CRISPR Therapeutics’ lead candidate, spurring a double-digit drop in the Swiss biotech’s stock value by Thursday morning. …
